Rona Therapeutics Announces $25 Million Pre-B Financing to Accelerate Global Clinical Pipeline and Innovative Drug Development

Mar 17, 2025 09:31 CST Updated 09:31

Rona Therapeutics

Nucleic Acid Drug Developer

｜Edited by the Content Team of Zhong Peptide Biochemicals

March 202514DayRona Therapeutics (Shanghai) Co., Ltd. ("Rona Therapeutics"), a clinical-stage platform company at the forefront of nucleic acid drug research and development, officially announced the successful completion of its Pre-B round of financing, raising US$25 million. This round of financing was led by Guanghua Wutong, with participation from new and existing shareholders including Lilly Asia Ventures, Jiangyuan Investment, and Boyuan Capital, fully demonstrating continued recognition of Rona Therapeutics' innovation in the field of nucleic acid drugs.Confidence.

This round of financing will help Rona Therapeutics advance its unique delivery and chemical modification platform technologies, further expand its siRNA clinical pipeline layout in the fields of cardiometabolic diseases, weight management, and other areas, and comprehensively enhance its large-scale production capabilities. The successful completion of this financing round is due to Rona Therapeutics' breakthrough progress in several key milestones, including the rapid advancement of its clinical pipeline and significant achievements in preclinical research. These developments not only validate the technological advantages of the company's innovative platform but also fully demonstrate its tremendous clinical potential in treating major diseases.

Stella SHI, CEO and founder of Rona Therapeutics, said: "We are greatly honored to receive strong support from GHW and both existing and new shareholders. This round of financing will provide us with powerful momentum to accelerate our R&D progress and push the technological boundaries, enabling us to bring more innovative and groundbreaking siRNA therapies to patients with unmet clinical needs worldwide."

Since its establishment in 2021, Rona Therapeutics has rapidly become a leader in the siRNA therapeutics field with its modular and programmable delivery and chemical modification platform. The company is committed to addressing hypercholesterolemia,Complex diseases such as hypertriglyceridemia, focusing on advancing human health through cutting-edge technologies. This Pre-B round of financing will provide strong support for Rona Therapeutics to accelerate clinical research progress and deepen the development of extrahepatic delivery systems.Further solidify its leading position in the global small nucleic acid drug field.

About Rona Therapeutics

Rona Therapeutics is a global leading nucleic acid innovative drug platform company, focusing on the treatment of metabolic diseases, weight loss, and other related conditions. Rona Therapeutics is committed to developing best-in-class and first-in-industry siRNA drugs with differentiation and innovation to address unmet clinical needs and improve treatment outcomes for cardiovascular diseases, obesity, and metabolic disorder-associated nonalcoholic steatohepatitis (NASH). Additionally, Rona Therapeutics is fully dedicated to unlocking the enormous potential of extrahepatic delivery technologies, such as fat and muscle delivery, for the treatment of various metabolic syndromes.

Source:

1. Rona Therapeutics